Estimating Lifetime Duration of Diabetes by Age and Gender in the Korean Population Using a Markov Model.
Cohort
Diabetes
Disability Adjusted Life Years
Duration
Markov Model
Journal
Journal of Korean medical science
ISSN: 1598-6357
Titre abrégé: J Korean Med Sci
Pays: Korea (South)
ID NLM: 8703518
Informations de publication
Date de publication:
26 Mar 2019
26 Mar 2019
Historique:
received:
08
11
2018
accepted:
23
01
2019
entrez:
30
3
2019
pubmed:
30
3
2019
medline:
8
6
2019
Statut:
epublish
Résumé
Duration of type 2 diabetes is clinically important. Duration of morbidity is an independent and critical predictor of developing its complications. This study aims to explore an applicability of a Markov model to estimate the duration of diabetes in the Korean population. We constructed the Markov model with two Markov states, diabetes and death, for estimation of duration of diabetes. The cycle of the Markov model was 1 year. Each diabetes onset by 5 years was considered from 30 to 85 years old or above. The endpoint of the Markov was 100 years old. Type 2 diabetes was operationally defined using the 10th revision of International Statistical Classification of Diseases and prescriptions of anti-diabetic drugs from the National Health Insurance Services-National Sample cohort. In each incident and existing prevalence cases, survival probabilities were obtained. Durations of diabetes from the Markov model were compared with those from the DisMod II program. Reductions of life expectancy due to diabetes were defined as differences of life expectancies between diabetic patients and the general public. Sensitivity analyses were also conducted using a cure rate and 95% confidence interval of survival probability. The duration of diabetes gradually decreased with incident age in both genders. In the early 30s, the duration was the largest at 48.9 and 41.9 years in women and men, respectively. In the average incident age group of type 2 diabetes, the late 50s, the reduction of life expectancy due to diabetes was estimated to be about two years in both genders. As annual cure probabilities increased, the durations of diabetes were reduced. This study estimated the duration of diabetes using a Markov model. The model seems to work well and diabetes could reduce life expectancy by about 2 years on average. This approach could be useful to estimate the duration of illness, calculate disability-adjusted life years, and conduct economic evaluation studies on interventions for diabetic patients.
Sections du résumé
BACKGROUND
BACKGROUND
Duration of type 2 diabetes is clinically important. Duration of morbidity is an independent and critical predictor of developing its complications. This study aims to explore an applicability of a Markov model to estimate the duration of diabetes in the Korean population.
METHODS
METHODS
We constructed the Markov model with two Markov states, diabetes and death, for estimation of duration of diabetes. The cycle of the Markov model was 1 year. Each diabetes onset by 5 years was considered from 30 to 85 years old or above. The endpoint of the Markov was 100 years old. Type 2 diabetes was operationally defined using the 10th revision of International Statistical Classification of Diseases and prescriptions of anti-diabetic drugs from the National Health Insurance Services-National Sample cohort. In each incident and existing prevalence cases, survival probabilities were obtained. Durations of diabetes from the Markov model were compared with those from the DisMod II program. Reductions of life expectancy due to diabetes were defined as differences of life expectancies between diabetic patients and the general public. Sensitivity analyses were also conducted using a cure rate and 95% confidence interval of survival probability.
RESULTS
RESULTS
The duration of diabetes gradually decreased with incident age in both genders. In the early 30s, the duration was the largest at 48.9 and 41.9 years in women and men, respectively. In the average incident age group of type 2 diabetes, the late 50s, the reduction of life expectancy due to diabetes was estimated to be about two years in both genders. As annual cure probabilities increased, the durations of diabetes were reduced.
CONCLUSION
CONCLUSIONS
This study estimated the duration of diabetes using a Markov model. The model seems to work well and diabetes could reduce life expectancy by about 2 years on average. This approach could be useful to estimate the duration of illness, calculate disability-adjusted life years, and conduct economic evaluation studies on interventions for diabetic patients.
Identifiants
pubmed: 30923487
doi: 10.3346/jkms.2019.34.e74
pmc: PMC6434151
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e74Déclaration de conflit d'intérêts
Disclosure: The authors have no potential conflicts of interest to disclose.
Références
Pharmacoeconomics. 1998 Apr;13(4):397-409
pubmed: 10178664
Diabetes Care. 2003 Feb;26(2):360-6
pubmed: 12547863
Popul Health Metr. 2003 Apr 14;1(1):4
pubmed: 12773212
Med Decis Making. 2004 Jul-Aug;24(4):351-8
pubmed: 15271273
Arch Intern Med. 2007 Jun 11;167(11):1145-51
pubmed: 17563022
Med Decis Making. 2008 Sep-Oct;28(5):706-12
pubmed: 18448700
Eur Heart J. 2009 Apr;30(7):834-9
pubmed: 19109355
Diabetes Care. 2009 Jan;32 Suppl 1:S62-7
pubmed: 19118289
Diabetes Care. 2009 Nov;32(11):2133-5
pubmed: 19875608
J Gerontol B Psychol Sci Soc Sci. 2010 May;65B(3):381-9
pubmed: 20028950
N Engl J Med. 2011 Mar 03;364(9):829-841
pubmed: 21366474
Popul Health Metr. 2012 Apr 24;10(1):7
pubmed: 22531113
Diabetologia. 2014 Dec;57(12):2465-74
pubmed: 25226881
Int J Ophthalmol. 2015 Feb 18;8(1):132-7
pubmed: 25709923
Int J Epidemiol. 2017 Apr 1;46(2):e15
pubmed: 26822938
Nat Med. 2016 Jul 7;22(7):709-11
pubmed: 27387884
Endocrine. 2017 Jan;55(1):66-76
pubmed: 27477292
Endocrinol Metab (Seoul). 2016 Sep;31(3):349-353
pubmed: 27586447
Cardiovasc Diabetol. 2016 Sep 13;15(1):131
pubmed: 27618811
Stat Med. 1989 Jul;8(7):831-43
pubmed: 2772443
J Korean Med Sci. 2016 Nov;31 Suppl 2:S146-S157
pubmed: 27775252
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3443-3451
pubmed: 28911137
Diabetes Care. 1993 Feb;16(2):434-44
pubmed: 8432214
Clin Infect Dis. 1998 Jul;27(1):185-90
pubmed: 9675475